Georgia's Online Cancer Information Center

Find A Clinical Trial

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

Cancer Type
Hematopoietic Malignancies
Non-Hodgkin Lymphoma
Unknown Primary
Trial Phase
Phase II
18 Years and older, Male and Female
Study Type
Protocol IDs
VT3996-202 (primary)
Study Sponsor
Viracta Therapeutics, Inc.


A Phase 2 study to evaluate the efficacy of nanatinostat in combination with
valganciclovir in patients with relapsed/refractory EBV-positive lymphomas


Patients with EBV-associated lymphomas have inferior outcomes with standard-of-care
therapies compared to those with EBV-negative disease. Nanatinostat is a selective class
I HDAC inhibitor which induces EBV lytic phase protein generation, activating
(val)ganciclovir to its cytotoxic form. This open-label, multicenter, multinational,
single-arm, Phase 2 basket study employs a Simon's 2-stage design to allow termination of
enrollment into cohorts where treatment appears futile, and will include the following
cohorts of patients with EBV+ relapsed/refractory lymphomas:

1. EBV+ diffuse large B-cell lymphoma (DLBCL, NOS)

2. Peripheral T-cell lymphoma (PTCL), including PTCL-NOS and AITL

3. Post-transplant lymphoproliferative disorder (PTLD)

4. EBV+ lymphoproliferative disorders other than the above, including Extranodal
NK/T-cell lymphoma (ENKTL)


  1. EBV+ DLBCL, NOS and PTCL, NOS, and AITL: Relapsed/refractory disease following 1 or more prior systemic therapy(ies) with curative intent.
  2. For EBV+ PTLD patients: Relapsed/refractory disease following 1 prior therapy and must have received at least 1 course of an anti-CD20 immunotherapy. For patients with EBV+ PTLD only, age 12 years and older and weighing greater than 40 kg (Adolescent, Adult, Older Adult) are allowed
  3. For other EBV+ relapsed/refractory lymphoma: Following at least 1 course of an anit-CD20 immunotherapy and at least 1 course of anthracycline-based chemotherapy (unless contraindicated)
  4. No available therapies in the opinion of the Investigator
  5. Not eligible for high-dose chemotherapy with allogeneic/autologous stem cell transplantation or CAR-T therapy
  6. Measurable disease per Cheson 2007
  7. ECOG performance status 0, 1, 2
  8. Adequate bone marrow function Key

Treatment Sites in Georgia

Winship Cancer Institute of Emory University

1365 Clifton Road NE
Building C
Atlanta, GA 30322

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.